Dorado JV Weighs New Design to Reduce Costs, Accelerate Oil Output
By David Winning
SYDNEY--A junior partner in the Santos-led Dorado oil project in Western Australia on Monday signaled construction costs would be less than prior guidance of $2 billion.
Carnarvon Energy said the joint venture is considering a reshaped design that would make better use of Dorado's proposed production facilities. This would reduce initial costs and could mean first oil from the project is produced sooner, the company said.
The venture has also identified several floating production storage and offloading units currently idled around the world that could improve the economics of the Dorado oil project, Carnarvon said.
"Carnarvon's estimates for upfront capital expenditure savings are expected to be material to the company," said Chief Executive Philip Huizenga.
He added the company's existing balance sheet would likely be able to fund its share of development costs under the optimized project, which the venture hopes to be in a position to approve by the end of this year.
Write to David Winning at david.winning@wsj.com
(END) Dow Jones Newswires
April 28, 2024 18:40 ET (22:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks